The injection to emerging adult workerbees with fluvalinate doses ranging from 1 femtomol to 1 nanomol per individual resulted in a reduction of haemolymph carbohydrate concentrations, particularly at the lowest dose ...The injection to emerging adult workerbees with fluvalinate doses ranging from 1 femtomol to 1 nanomol per individual resulted in a reduction of haemolymph carbohydrate concentrations, particularly at the lowest dose 1 hour after injections. At the same time, a large increase was observed for triacylglycerols and to a much lesser extent for steroids and phospholipids with 0.1 picomol per bee. By contrast, fatty acids, steroids and triacylglycerols exhibited a depress at the higher dose. Most responses were thus biphasic, showing that much attention should be paid to the effects of very low doses of pesticide.展开更多
Background Increasing studies were designed to administer a low beneficial outcomes. However, the appropriate dose via coronary for intervention with acute ST-segment elevation myocardial infarction bolus of intracoro...Background Increasing studies were designed to administer a low beneficial outcomes. However, the appropriate dose via coronary for intervention with acute ST-segment elevation myocardial infarction bolus of intracoronary tirofiban to achieve patients undergoing percutaneous coronary （STEMI） is needed to be investigated. Methods Eighty three patients with STEMI presented within 12 hrs of symptoms were randomly allocated to high-dose group （n = 28）, low-dose group （n = 35） and control group （n = 30）. The culprit vessels were targeted with primary PCI in all patients. Clinical characteristics, angiographic findings, brain natriuretic peptide （BNP） at 7-day and in-hospital outcomes were compared among groups, as well as left ventricular ejection fraction （LVEF） and major adverse cardiac events （MACE） at 30-day clinical follow-up. Results High-dose and low-dose groups showed better thrombolysis in myocardial infarction （TIMI） flow grades immediately after PCI （P = 0.02） and lower incidence of the 30-day composite major cardiac adverse events than the control group, but there was not significant difference between high-dose and low-dose group. The LVEF and BNP in the studied groups at 7 days were better than those in the control group （P = 0.04 and P = 0.04, respectively）. No significant difference in hemorrhagic complications in hospital between groups were noted （P = 0.76）. Conclusions Intracoronary bolus administration of tirofiban for patients with STEMI undergoing primary PCI can improve the reperfusion level in the infarcted area and clinical outcomes in 30-day follow-up. It is superior to intravenous bolus injection for improving coronary flow, LVEF and short-term clinical outcomes. However, increasing dose of intracoronary tirofiban doesn＇t show significant differences.展开更多
文摘The injection to emerging adult workerbees with fluvalinate doses ranging from 1 femtomol to 1 nanomol per individual resulted in a reduction of haemolymph carbohydrate concentrations, particularly at the lowest dose 1 hour after injections. At the same time, a large increase was observed for triacylglycerols and to a much lesser extent for steroids and phospholipids with 0.1 picomol per bee. By contrast, fatty acids, steroids and triacylglycerols exhibited a depress at the higher dose. Most responses were thus biphasic, showing that much attention should be paid to the effects of very low doses of pesticide.
文摘Background Increasing studies were designed to administer a low beneficial outcomes. However, the appropriate dose via coronary for intervention with acute ST-segment elevation myocardial infarction bolus of intracoronary tirofiban to achieve patients undergoing percutaneous coronary （STEMI） is needed to be investigated. Methods Eighty three patients with STEMI presented within 12 hrs of symptoms were randomly allocated to high-dose group （n = 28）, low-dose group （n = 35） and control group （n = 30）. The culprit vessels were targeted with primary PCI in all patients. Clinical characteristics, angiographic findings, brain natriuretic peptide （BNP） at 7-day and in-hospital outcomes were compared among groups, as well as left ventricular ejection fraction （LVEF） and major adverse cardiac events （MACE） at 30-day clinical follow-up. Results High-dose and low-dose groups showed better thrombolysis in myocardial infarction （TIMI） flow grades immediately after PCI （P = 0.02） and lower incidence of the 30-day composite major cardiac adverse events than the control group, but there was not significant difference between high-dose and low-dose group. The LVEF and BNP in the studied groups at 7 days were better than those in the control group （P = 0.04 and P = 0.04, respectively）. No significant difference in hemorrhagic complications in hospital between groups were noted （P = 0.76）. Conclusions Intracoronary bolus administration of tirofiban for patients with STEMI undergoing primary PCI can improve the reperfusion level in the infarcted area and clinical outcomes in 30-day follow-up. It is superior to intravenous bolus injection for improving coronary flow, LVEF and short-term clinical outcomes. However, increasing dose of intracoronary tirofiban doesn＇t show significant differences.
